Health Catalyst Reports First Quarter 2023 Results

Health Catalyst Reports First Quarter 2023 Results

May 09, 2023 | Last Trade: US$7.70 0.34 -4.23

SALT LAKE CITY, May 09, 2023 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2023.

“In the first quarter of 2023, I am pleased to share that we achieved strong performance across our business, including exceeding the mid-point of our quarterly guidance for both revenue and Adjusted EBITDA. This financial performance demonstrates our ability to continue to scale our business as we drive toward our long-term profitability goals,” said Dan Burton, CEO of Health Catalyst. “Additionally, I am excited to announce a meaningful expansion of our tech-enabled managed services partnership with our longest-standing client, Allina Health. This expansion, which includes more chart abstraction responsibility, increases Allina’s recurring revenue to now be approximately $11 million per year. We continue to appreciate Allina’s multi-faceted partnership and trust in Health Catalyst since the beginning of our relationship with them nearly 15 years ago, and we are encouraged to see other potential areas of expansion with them in the future.”

Financial Highlights for the Three Months Ended March 31, 2023

Key Financial Metrics

	Three Months Ended March 31,						Year over Year Change
		2023			2022		Year over Year Change
GAAP Financial Data:	(in thousands, except percentages, unaudited)
Technology revenue	$	47,186		$	42,230		12	%
Professional services revenue	$	26,682		$	25,857		3	%
Total revenue	$	73,868		$	68,087		8	%
Loss from operations	$	(34,914	)	$	(24,347	)	(43	)%
Net loss	$	(33,190	)	$	(22,458	)	(48	)%
Other Non-GAAP Financial Data:⁽¹⁾
Adjusted Technology Gross Profit	$	32,958		$	29,598		11	%
Adjusted Technology Gross Margin		70	%		70	%
Adjusted Professional Services Gross Profit	$	5,414		$	7,574		(29	)%
Adjusted Professional Services Gross Margin		20	%		29	%
Total Adjusted Gross Profit	$	38,372		$	37,172		3	%
Total Adjusted Gross Margin		52	%		55	%
Adjusted EBITDA	$	4,164		$	671		521	%

(1)

These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the second quarter of 2023, we expect:

Total revenue between $70.3 million and $74.3 million, and
Adjusted EBITDA between $0.75 million and $4.75 million

For the full year of 2023, we expect:

Total revenue between $290.0 million and $295.0 million, and
Adjusted EBITDA between $9.0 million and $11.0 million

We have not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and have not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within our control or cannot be reasonably forecasted.

Quarterly Conference Call Details

The company will host a conference call to review the results today, Tuesday, May 9, 2023, at 5:00 p.m. E.T. The conference call can be accessed by dialing (800) 225-9448 for U.S. participants, or (203) 518-9708 for international participants, and referencing conference ID “HCAT Q123.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform — powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including our website (https://www.healthcatalyst.com/), our investor relations website (https://ir.healthcatalyst.com/), press releases, SEC filings, public conference calls, and social media, including our and our CEO's social media accounts, in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for Q2 and fiscal year 2023. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to our technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners; (v) the impact of the challenging macroeconomic environment (including high inflationary and/or high interest rate environments) on our business and results of operations; and (vi) changes to our abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 expected to be filed with the SEC on or about May 9, 2023 and the Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 28, 2023. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.


Condensed Consolidated Balance Sheets (in thousands, except share and per share data, unaudited)

	As of March 31,			As of December 31,
		2023			2022
	(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	133,479		$	116,312
Short-term investments		223,448			247,178
Accounts receivable, net		61,862			47,970
Prepaid expenses and other assets		15,728			16,335
Total current assets		434,517			427,795
Property and equipment, net		26,441			25,928
Operating lease right-of-use assets		16,161			16,658
Intangible assets, net		84,410			92,189
Goodwill		185,982			185,982
Other assets		4,790			3,734
Total assets	$	752,301		$	752,286
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	9,243		$	4,424
Accrued liabilities		23,953			19,691
Deferred revenue		65,905			54,961
Operating lease liabilities		3,394			3,434
Total current liabilities		102,495			82,510
Convertible senior notes		226,900			226,523
Deferred revenue, net of current portion		189			105
Operating lease liabilities, net of current portion		17,448			18,017
Other liabilities		123			121
Total liabilities		347,155			327,276

Commitments and contingencies

Stockholders’ equity:
Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2023 and December 31, 2022		—			—
Common stock, $0.001 par value per share, and additional paid in capital; 500,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 55,843,457 and 55,261,922 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively		1,437,654			1,424,681
Additional paid-in capital
Accumulated deficit		(1,032,213	)		(999,023	)
Accumulated other comprehensive loss		(295	)		(648	)
Total stockholders’ equity		405,146			425,010
Total liabilities and stockholders’ equity	$	752,301		$	752,286


Condensed Consolidated Statements of Operations (in thousands, except per share data, unaudited)

	Three Months Ended March 31,
		2023			2022
	(in thousands)
Revenue:
Technology	$	47,186		$	42,230
Professional services		26,682			25,857
Total revenue		73,868			68,087
Cost of revenue, excluding depreciation and amortization shown below:
Technology^(1)(2)(3)		14,727			13,327
Professional services^(1)(2)(3)		23,577			20,669
Total cost of revenue, excluding depreciation and amortization		38,304			33,996
Operating expenses:
Sales and marketing^(1)(2)(3)		18,569			20,818
Research and development^(1)(2)(3)		17,082			17,148
General and administrative^(1)(2)(3)(4)		23,833			8,823
Depreciation and amortization		10,994			11,649
Total operating expenses		70,478			58,438
Loss from operations		(34,914	)		(24,347	)
Interest and other expense, net		1,793			(1,662	)
Loss before income taxes		(33,121	)		(26,009	)
Income tax provision (benefit)⁽²⁾		69			(3,551	)
Net loss	$	(33,190	)	$	(22,458	)
Net loss per share, basic	$	(0.60	)	$	(0.42	)
Net loss per share, diluted	$	(0.60	)	$	(0.54	)
Weighted-average shares outstanding used in calculating net loss per share, basic		55,485			53,007
Weighted-average shares outstanding used in calculating net loss per share, diluted		55,485			53,215

_______________
(1) Includes stock-based compensation expense as follows:

	Three Months Ended March 31,
		2023		2022
Stock-Based Compensation Expense:	(in thousands)
Cost of revenue, excluding depreciation and amortization:
Technology	$	416	$	589
Professional services		1,774		2,167
Sales and marketing		5,442		7,013
Research and development		2,673		3,090
General and administrative		3,579		5,261
Total	$	13,884	$	18,120

(2) Includes acquisition-related costs (benefit), net, as follows:

	Three Months Ended March 31,
		2023		2022
Acquisition-related costs (benefit), net:	(in thousands)
Cost of revenue, excluding depreciation and amortization:
Technology	$	71	$	106
Professional services		101		219
Sales and marketing		101		397
Research and development		194		558
General and administrative		14		(6,031	)
Income tax provision (benefit)		—		(3,600	)
Total	$	481	$	(8,351	)

(3) Includes restructuring costs, as follows:

	Three Months Ended March 31,
		2023		2022
Restructuring costs:	(in thousands)
Cost of revenue, excluding depreciation and amortization:
Technology	$	12	$	—
Professional services		434		—
Sales and marketing		1,205		—
Research and development		286		—
General and administrative		118		—
Total	$	2,055	$	—

(4) Includes litigation costs, as follows:

	Three Months Ended March 31,
		2023		2022
Litigation costs:	(in thousands)
General and administrative	$	11,664	$	—
Total	$	11,664	$	—


Condensed Consolidated Statements of Cash Flows (in thousands, unaudited)

	Three Months Ended March 31,
		2023			2022
Cash flows from operating activities
Net loss	$	(33,190	)	$	(22,458	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		13,884			18,120
Depreciation and amortization		10,994			11,649
Change in fair value of contingent consideration liabilities		—			(8,424	)
Non-cash operating lease expense		764			819
Investment (discount) premium amortization		(1,979	)		398
Amortization of debt discount and issuance costs		377			374
Provision for expected credit losses		1,514			200
Deferred tax provision (benefit)		2			(3,598	)
Other		19			(49	)
Change in operating assets and liabilities:
Accounts receivable, net		(15,405	)		6,019
Prepaid expenses and other assets		(420	)		437
Accounts payable, accrued liabilities, and other liabilities		7,709			(4,812	)
Deferred revenue		11,027			4,106
Contingent consideration liabilities		—			(741	)
Operating lease liabilities		(876	)		(882	)
Net cash (used in) provided by operating activities		(5,580	)		1,158

Cash flows from investing activities
Proceeds from the sale and maturity of short-term investments		107,100			80,960
Purchase of short-term investments		(81,070	)		(56,719	)
Acquisition of business, net of cash acquired		—			(18,509	)
Capitalization of internal-use software		(2,864	)		(3,261	)
Purchase of intangible assets		(98	)		(463	)
Purchase of property and equipment		(425	)		(356	)
Proceeds from the sale of property and equipment		6			4
Net cash provided by investing activities		22,649			1,656

Cash flows from financing activities
Proceeds from exercise of stock options		727			1,809
Proceeds from employee stock purchase plan		1,174			1,509
Repurchase of common stock		(1,808	)		—
Payments of acquisition-related consideration		—			(930	)
Net cash provided by financing activities		93			2,388
Effect of exchange rate changes on cash and cash equivalents		5			(1	)
Net increase in cash and cash equivalents		17,167			5,201

Cash and cash equivalents at beginning of period		116,312			193,227
Cash and cash equivalents at end of period	$	133,479		$	198,428

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with GAAP, we believe certain non-GAAP measures, including Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA, Adjusted Net Loss, and Adjusted Net Loss per share, basic and diluted, are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because it is non-cash in nature and excluding this expense provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We use this non-GAAP financial information to evaluate our ongoing operations, as a component in determining employee bonus compensation, and for internal planning and forecasting purposes.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted Gross Profit is a non-GAAP financial measure that we define as revenue less cost of revenue, excluding depreciation and amortization, adding back stock-based compensation, acquisition-related costs, net, and restructuring costs as applicable. We define Adjusted Gross Margin as our Adjusted Gross Profit divided by our revenue. We believe Adjusted Gross Profit and Adjusted Gross Margin are useful to investors as they eliminate the impact of certain non-cash expenses and allow a direct comparison of these measures between periods without the impact of non-cash expenses and certain other non-recurring operating expenses. The following is a reconciliation of revenue, the most directly comparable GAAP financial measure, to Adjusted Gross Profit, for the three months ended March 31, 2023 and 2022:

	Three Months Ended March 31, 2023
	(in thousands, except percentages)
	Technology			Professional Services			Total
Revenue	$	47,186		$	26,682		$	73,868
Cost of revenue, excluding depreciation and amortization		(14,727	)		(23,577	)		(38,304	)
Gross profit, excluding depreciation and amortization		32,459			3,105			35,564
Add:
Stock-based compensation		416			1,774			2,190
Acquisition-related costs, net⁽¹⁾		71			101			172
Restructuring costs⁽²⁾		12			434			446
Adjusted Gross Profit	$	32,958		$	5,414		$	38,372
Gross margin, excluding depreciation and amortization		69	%		12	%		48	%
Adjusted Gross Margin		70	%		20	%		52	%

(1)	Acquisition-related costs, net include deferred retention expenses following the KPI Ninja and ARMUS acquisitions.
(2)	Restructuring costs include severance and other team member costs from workforce reductions.

	Three Months Ended March 31, 2022
	(in thousands, except percentages)
	Technology			Professional Services			Total
Revenue	$	42,230		$	25,857		$	68,087
Cost of revenue, excluding depreciation and amortization		(13,327	)		(20,669	)		(33,996	)
Gross profit, excluding depreciation and amortization		28,903			5,188			34,091
Add:
Stock-based compensation		589			2,167			2,756
Acquisition-related costs, net⁽¹⁾		106			219			325
Adjusted Gross Profit	$	29,598		$	7,574		$	37,172
Gross margin, excluding depreciation and amortization		68	%		20	%		50	%
Adjusted Gross Margin		70	%		29	%		55	%

(1)	Acquisition-related costs, net include deferred retention expenses following the KPI Ninja and Twistle acquisitions.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net loss adjusted for (i) interest and other (income) expense, net, (ii) income tax provision (benefit), (iii) depreciation and amortization, (iv) stock-based compensation, (v) acquisition-related costs, net, (vi) litigation costs, and (vii) restructuring costs. We view acquisition-related expenses when applicable, such as transaction costs and changes in the fair value of contingent consideration liabilities that are directly related to business combinations, as costs that are unpredictable, dependent upon factors outside of our control, and are not necessarily reflective of operational performance during a period. We believe that excluding restructuring costs and litigation costs allows for more meaningful comparisons between operating results from period to period as these are separate from the core activities that arise in the ordinary course of our business and are not part of our ongoing operations. We believe Adjusted EBITDA provides investors with useful information on period-to-period performance as evaluated by management and a comparison with our past financial performance, and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. The following is a reconciliation of our net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA, for the three months ended March 31, 2023 and 2022:

	Three Months Ended March 31,
		2023			2022
	(in thousands)
Net loss	$	(33,190	)	$	(22,458	)
Add:
Interest and other (income) expense, net		(1,793	)		1,662
Income tax provision (benefit)		69			(3,551	)
Depreciation and amortization		10,994			11,649
Stock-based compensation		13,884			18,120
Acquisition-related costs, net⁽¹⁾		481			(4,751	)
Litigation costs⁽²⁾		11,664			—
Restructuring costs⁽³⁾		2,055			—
Adjusted EBITDA	$	4,164		$	671

(1)	Current year acquisition-related costs, net includes deferred retention expenses, while the prior year acquisition-related costs, net include third-party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, and changes in fair value of contingent consideration liabilities for potential earn-out payments. For additional details refer to Note 2 in our condensed consolidated financial statements.
(2)	Litigation costs include costs related to litigation that are outside the ordinary course of our business. For additional details, refer to Notes 8 and 14 in our condensed consolidated financial statements.
(3)	Restructuring costs include severance and other team member costs from workforce reductions. For additional details, refer to Note 18 in our condensed consolidated financial statements.

Adjusted Net Income (Loss) Per Share

Adjusted Net Income (Loss) is a non-GAAP financial measure that we define as net loss adjusted for (i) stock-based compensation, (ii) amortization of acquired intangibles, (iii) acquisition-related costs, net, including the change in fair value of contingent consideration liabilities and the deferred tax valuation allowance release from acquisitions, (iv) litigation costs, (v) restructuring costs, and (vi) non-cash interest expense related to our convertible senior notes. We believe Adjusted Net Income (Loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

	Three Months Ended March 31,
		2023			2022
Numerator:	(in thousands, except share and per share amounts)
Net loss	$	(33,190	)	$	(22,458	)
Add:
Stock-based compensation		13,884			18,120
Amortization of acquired intangibles		7,780			9,348
Acquisition-related costs, net⁽¹⁾		481			(8,351	)
Litigation costs⁽²⁾		11,664			—
Restructuring costs⁽³⁾		2,055			—
Non-cash interest expense related to convertible senior notes		377			374
Adjusted Net Income (Loss)	$	3,051		$	(2,967	)
Denominator:
Weighted-average number of shares used in calculating net loss per share, basic		55,484,835			53,006,704
Non-GAAP weighted-average effect of dilutive securities		792,630			—
Non-GAAP weighted-average number of shares used in calculating Adjusted Net Income (Loss) per share, diluted		56,277,465			53,006,704

Adjusted Net Income (Loss) per share, basic	$	0.05		$	(0.06	)
Adjusted Net Income (Loss) per share, diluted	$	0.05		$	(0.06	)

(1)	Current year acquisition-related costs, net includes deferred retention expenses, while the prior year acquisition-related costs, net include third party fees associated with due diligence, deferred retention expenses, post-acquisition restructuring costs incurred as part of business combinations, changes in fair value of contingent consideration liabilities for potential earn-out payments, and the deferred tax valuation allowance release from the 2022 acquisition of KPI Ninja. For additional details refer to Notes 1, 2, and 13 in our condensed consolidated financial statements.
(2)	Litigation costs include costs related to litigation that are outside the ordinary course of our business. For additional details, refer to Notes 8 and 14 in our condensed consolidated financial statements.
(3)	Restructuring costs include severance and other team member costs from workforce reductions. For additional details, refer to Note 18 in our condensed consolidated financial statements.

Health Catalyst Investor Relations Contact:
Adam Brown
Senior Vice President, Investor Relations and FP&A
+1 (855)-309-6800
This email address is being protected from spambots. You need JavaScript enabled to view it.

Health Catalyst Media Contact:
Tarah Neujahr Bryan
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$7.70
Daily Change:	-0.34 -4.23
Daily Volume:	376,672
Market Cap:	US$465.620M

August 27, 2024 WISHIN Expands Relationship with Health Catalyst, Signing Multi-Year Partnership to Migrate to Ninja Universe™ Suite August 08, 2024 Health Catalyst Announces Partnership Expansion with Western U.S.'s Largest Health Information Exchange, Contexture August 08, 2024 Health Catalyst and South Dakota Health Link Expand Partnership to Improve the Quality and Effectiveness of Healthcare in the Midwest August 07, 2024 Health Catalyst Reports Second Quarter 2024 Results May 21, 2024 Health Catalyst Unveils Next-Generation Data and Analytics Ecosystem Built for Healthcare, Health Catalyst Ignite® LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE